Tenax Therapeutics, focusing on oral levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), reported steady progress in its ongoing Phase 3 LEVEL and LEVEL-2 trials as of Q1 2026. The company has deferred advancement of imatinib and strengthened its capital base through recent financing rounds, ensuring adequate runway for clinical milestones. Leveraging repurposed drugs with established safety profiles and exclusive licensing rights, Tenax targets a large unmet need in a novel indication with no approved therapies. Key risks include clinical and regulatory uncertainties alongside the necessity for future capital raises.